Galinpepimut-S

Drug Profile

Galinpepimut-S

Alternative Names: FPI-01; SLS-001; WT-1 analog peptide vaccine; WT1 cancer vaccine - SELLAS Life Sciences; WT1 peptide vaccine - Memorial Sloan Kettering; WT1 vaccine - Memorial Sloan Kettering; ZELTHERVA

Latest Information Update: 04 Mar 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Advaxis; Memorial Sloan-Kettering Cancer Center; Sellas Life Sciences Group
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute myeloid leukaemia; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Mesothelioma
  • Phase I/II Multiple myeloma; Ovarian cancer
  • Phase I Fallopian tube cancer; Peritoneal cancer
  • Research Cancer

Most Recent Events

  • 01 Mar 2017 SELLAS Life Sciences plans a phase III trial for Acute myeloid leukaemia
  • 01 Mar 2017 SELLAS Life Sciences plans a phase III trial for Mesothelioma in USA and Europe
  • 01 Mar 2017 Efficacy data from a phase II trial in Multiple myeloma released by SELLAS Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top